Literature DB >> 11844864

Cerivastatin and reports of fatal rhabdomyolysis.

Judy A Staffa, Jennie Chang, Lanh Green.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11844864     DOI： 10.1056/NEJM200202143460721

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  124 in total

1.  Rhabdomyolysis and cerivastatin: was it a problem of dose?

Authors:  Dipen Kalaria; Willem Wassenaar
Journal:  CMAJ       Date:  2002-10-01       Impact factor: 8.262

Review 2.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

Review 4.  Pharmacoeconomics of lipid-lowering drugs.

Authors:  Dean G Smith
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 5.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.

Authors:  M R Law; N J Wald; A R Rudnicka
Journal:  BMJ       Date:  2003-06-28

Review 6.  Toxicity of antilipidemic agents: facts and fictions.

Authors:  Antonios M Xydakis; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

7.  Statins and the risk of rhabdomyolysis.

Authors:  R S Rosenson
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

8.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

9.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage.

Authors:  J H Tapia-Pérez; R Rupa; R Zilke; S Gehring; B Voellger; T Schneider
Journal:  Neurosurg Rev       Date:  2012-10-25       Impact factor: 3.042
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.